NasdaqGM:RMTI

Stock Analysis Report

Executive Summary

Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • Rockwell Medical has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Rockwell Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.0%

NasdaqGM:RMTI

-0.08%

US Medical Equipment

0.2%

US Market


1 Year Return

-41.4%

NasdaqGM:RMTI

14.1%

US Medical Equipment

-0.7%

US Market

RMTI underperformed the Medical Equipment industry which returned 14.7% over the past year.

RMTI underperformed the Market in United States of America which returned 0.3% over the past year.


Share holder returns

RMTIIndustryMarket
7 Day-2.0%-0.08%0.2%
30 Day-17.9%0.5%-2.7%
90 Day-48.5%10.2%1.6%
1 Year-41.4%-41.4%15.0%14.1%1.6%-0.7%
3 Year-65.8%-65.8%68.4%63.2%40.0%30.9%
5 Year-73.5%-73.5%131.5%104.9%53.8%36.8%

Price Volatility Vs. Market

How volatile is Rockwell Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Rockwell Medical undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Rockwell Medical's share price is below the future cash flow value, and at a moderate discount (> 20%).

Rockwell Medical's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Rockwell Medical is loss making, we can't compare its value to the US Medical Equipment industry average.

Rockwell Medical is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Rockwell Medical, we can't assess if its growth is good value.


Price Based on Value of Assets

Rockwell Medical is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Rockwell Medical expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

66.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Rockwell Medical's revenue is expected to grow significantly at over 20% yearly.

Rockwell Medical's earnings are expected to grow significantly at over 20% yearly.

Rockwell Medical's revenue growth is expected to exceed the United States of America market average.

Rockwell Medical's earnings growth is expected to exceed the United States of America market average.

Rockwell Medical's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Rockwell Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Rockwell Medical performed over the past 5 years?

-11.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Rockwell Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Rockwell Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Rockwell Medical's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Rockwell Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Rockwell Medical has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Rockwell Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Rockwell Medical's financial position?


Financial Position Analysis

Rockwell Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Rockwell Medical's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Rockwell Medical's level of debt (6.4%) compared to net worth is satisfactory (less than 40%).

Rockwell Medical had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 25.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Rockwell Medical has sufficient cash runway for 1.3 years based on current free cash flow.

Rockwell Medical has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 19.3% each year.


Next Steps

Dividend

What is Rockwell Medical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Rockwell Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Rockwell Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Rockwell Medical has not reported any payouts.

Unable to verify if Rockwell Medical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Rockwell Medical has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Rockwell Medical's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Stuart Paul (59yo)

0.9yrs

Tenure

US$7,483,803

Compensation

Mr. Stuart Paul is Chief Executive Officer and Director at Rockwell Medical, Inc. since September 04, 2018 and also serves as it's President. He served as the President of Asia & Pacific (APAC) at Gambro R ...


CEO Compensation Analysis

Stuart's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Stuart to compare compensation growth.


Management Age and Tenure

0.8yrs

Average Tenure

59yo

Average Age

The average tenure for the Rockwell Medical management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.9yrs

Average Tenure

59.5yo

Average Age

The tenure for the Rockwell Medical board of directors is about average.


Insider Trading

More shares have been bought than sold by Rockwell Medical individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$5,04102 Aug 19
Matthew Curfman
EntityIndividual
Shares1,904
Max PriceUS$2.66
BuyUS$8,07226 Jul 19
Matthew Curfman
EntityIndividual
Shares2,579
Max PriceUS$3.13
BuyUS$97626 Jul 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares319
Max PriceUS$3.06
BuyUS$475,88123 Jul 19
Richmond Brothers, Inc.
EntityCompany
Shares161,457
Max PriceUS$2.99
BuyUS$16,81010 Jul 19
Matthew Curfman
EntityIndividual
Shares5,519
Max PriceUS$3.05
BuyUS$11,14210 Jul 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares3,658
Max PriceUS$3.05
BuyUS$1,83710 Jul 19
David Richmond
EntityIndividual
Shares603
Max PriceUS$3.05
BuyUS$29,70003 Jul 19
Stuart Paul
EntityIndividual
Role
Chief Executive Officer
President
Shares10,000
Max PriceUS$2.97
BuyUS$30,60003 Jul 19
Angus Smith
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares10,000
Max PriceUS$3.06
BuyUS$026 Jun 19
Richmond Brothers, Inc.
EntityCompany
Shares50,775
Max PriceUS$5.58
SellUS$026 Jun 19
Richmond Brothers, Inc.
EntityCompany
Shares17,863
Max PriceUS$5.11
BuyUS$7,00026 Jun 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares1,240
Max PriceUS$5.65
BuyUS$2,85713 May 19
David Richmond
EntityIndividual
Shares506
Max PriceUS$5.65
BuyUS$11,37513 May 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares2,015
Max PriceUS$5.65
BuyUS$11,97913 May 19
Matthew Curfman
EntityIndividual
Shares2,122
Max PriceUS$5.65
BuyUS$1,27429 Mar 19
Matthew Curfman
EntityIndividual
Shares228
Max PriceUS$5.59
BuyUS$22,83329 Mar 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares4,087
Max PriceUS$5.59
BuyUS$8,68229 Mar 19
David Richmond
EntityIndividual
Shares1,554
Max PriceUS$5.59
BuyUS$43,24528 Mar 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares7,655
Max PriceUS$6.14
SellUS$35,31028 Mar 19
Richmond Brothers, Inc.
EntityCompany
Shares7,863
Max PriceUS$6.60
BuyUS$57,89328 Mar 19
Richmond Brothers, Inc.
EntityCompany
Shares15,114
Max PriceUS$6.55
SellUS$661,28717 Oct 18
Richmond Brothers, Inc.
EntityCompany
Shares134,531
Max PriceUS$4.92

Ownership Breakdown


Management Team

  • Ajay Gupta (61yo)

    Chief Scientific Officer & Member of Scientific Advisory Board

    • Tenure: 13.8yrs
    • Compensation: US$954.42k
  • Stuart Paul (59yo)

    President

    • Tenure: 0.9yrs
    • Compensation: US$7.48m
  • Jim McCarthy

    Senior Vice President of Business & Corporate Development

    • Tenure: 0.9yrs
  • Ray Pratt (68yo)

    Chief Medical Officer

    • Tenure: 7.3yrs
    • Compensation: US$965.87k
  • Angus Smith (36yo)

    Chief Financial Officer

    • Tenure: 0.8yrs
    • Compensation: US$1.45m
  • Anne Boardman

    Vice President of Sales and Strategic Accounts

    • Tenure: 0.8yrs
  • Charlie Shiner

    Vice President of Marketing

    • Tenure: 0.7yrs
  • Mike DeYoung

    Vice President of Operations

    • Tenure: 0.7yrs
  • Michael Costello

    General Counsel

    • Tenure: 0.0yrs
  • Paul McGarry (51yo)

    VP, Corporate Controller & Principal Accounting Officer

    • Tenure: 0.2yrs

Board Members

  • John Cooper (60yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: US$286.19k
  • Robin Smith (54yo)

    Director

    • Tenure: 3.2yrs
    • Compensation: US$193.16k
  • Lisa Colleran (61yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: US$246.15k
  • Ben Wolin (43yo)

    Chairman

    • Tenure: 1.4yrs
    • Compensation: US$306.85k
  • Ajay Gupta (61yo)

    Chief Scientific Officer & Member of Scientific Advisory Board

    • Tenure: 13.8yrs
    • Compensation: US$954.42k
  • Rajiv Agarwal

    Member of Scientific Advisory Board

    • Tenure: 13.8yrs
  • Stuart Paul (59yo)

    President

    • Tenure: 0.9yrs
    • Compensation: US$7.48m
  • Iain MacDougall

    Member of Scientific Advisory Board

    • Tenure: 9.0yrs
  • Alvin Crumbliss

    Member of Scientific Advisory Board

    • Tenure: 8.3yrs
  • Francesco Locatelli

    Member of Scientific Advisory Board

    • Tenure: 6.6yrs

Company Information

Rockwell Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Rockwell Medical, Inc.
  • Ticker: RMTI
  • Exchange: NasdaqGM
  • Founded: 1994
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$158.285m
  • Shares outstanding: 63.82m
  • Website: https://www.rockwellmed.com

Number of Employees


Location

  • Rockwell Medical, Inc.
  • 30142 Wixom Road
  • Wixom
  • Michigan
  • 48393
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RMTINasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJan 1998
RWMDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1998

Biography

Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and he ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 23:46
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.